Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Rhea-AI Summary

Revive Therapeutics (OTCQB: RVVTF) provided an update on an ongoing research study evaluating bucillamine as a potential treatment for nerve agent–induced brain injury.

The study is conducted in collaboration with Defence R&D Canada – Suffield Research Centre (DRDC), which is evaluating pharmacological compounds that may mitigate nerve agent effects. The study remains in progress and final findings will be released only with DRDC authorization. Revive said it will provide further updates as the study advances toward completion.

News Market Reaction

-5.43%

1 alert

-5.43% News Effect

On the day this news was published, RVVTF declined 5.43%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical countermeasures. DRDC is evaluating pharmacological compounds, including Bucillamine, that may mitigate nerve agent–induced brain injury.

The research study evaluating Bucillamine remains in progress, and the Company is awaiting the final findings, which will be released only with the express authorization of DRDC. Revive will continue to provide updates on the DRDC study as it advances toward completion.

About Revive Therapeutics Ltd.

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin and molecular hydrogen therapeutics through various programs. For more information, visit www.ReviveThera.com.

For more information, please contact:

Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the year ended June 30, 2025 ("MD&A"), dated October 28, 2025, which is available on the Company's profile at www.sedarplus.ca.

FAQ

What did Revive Therapeutics (RVVTF) announce on November 21, 2025 about bucillamine?

Revive announced an update that the DRDC‑led study evaluating bucillamine for nerve agent brain injury remains in progress and final findings await DRDC authorization.

Who is conducting the nerve agent countermeasure study for RVVTF?

The study is being conducted in collaboration with Defence R&D Canada – Suffield Research Centre (DRDC), an agency within the Canadian Department of National Defence.

Will Revive Therapeutics release the DRDC study results on its own timeline?

No; final findings will be released only with the express authorization of DRDC, per the company announcement.

Does the November 21, 2025 update include clinical or financial results for RVVTF?

No; the update states the research study remains in progress and does not include clinical readouts or financial data.

What is the focus of DRDC's evaluation mentioned by Revive (RVVTF)?

DRDC is evaluating pharmacological compounds, including bucillamine, that may mitigate nerve agent–induced brain injury.

Will Revive provide more updates on the DRDC study for RVVTF investors?

Yes; Revive said it will continue to provide updates as the DRDC study advances toward completion.